Stem Cell Innovations

Stem cell based drug discovery & development services

Orignating from a merger of Amphioxus Cell Technologies with Interferon Sciences in 2006, Stem Cell Innovations is supporting drug discovery by developing a methodology for the early selection of relevant compounds.

The company is headquartered in Houston, Texas, and has an additional research center and offices in The Hague, The Netherlands.

James H. Kelly, PhD, President, CEO
Lawrence M. Gordon, Assistent
Helmuth van Es, PhD, CSO Europe
Ian Lyons, PhD, CSO USA
Ivo Piest, Senior Director Business & Corporate Development

Mark Germain, Chairman
James H. Kelly, PhD
Lucio A. Noto
Tony Coelho
John Macomber
Norman Sussman, MD

11222 Richmond Ave., Suite 180
Houston, TX 77082-2646
USA
Phone:+1-281-679-7900/ ext. 19
Fax:+1-281-679-7910

Stem Cell Innovations focuses on cell biology. The company uses a human embryonic germ stem cell platform for the toxicity testing of drug candidates.

ACTIVTox® was developed to represent liver cells and to find possible reactions to drugs caused by toxication. In the future, the system might be used to simulate also other major organs.

PREDICTIVTox® is a predictive hepatotoxitity database including thousands of compounds.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.